JN-International Medical Corporation

JN-International Medical Corporation, commonly abbreviated JNIMC, was a privately held U.S. biopharmaceutical company focused on vaccines and diagnostic technologies for infectious diseases affecting underserved populations. The company was founded in 1998 in Oakland, Nebraska, by Dr. Jeeri R. Reddy, with assistance from Dr. Kelly F. Lechtenberg. It was initially known as Jeeri Neotech International, Inc. and later expanded its operations to Omaha in 2000. The company’s stated focus was the development and manufacture of products intended for use in regions where malaria, HIV/AIDS, tuberculosis, and bacterial meningitis represented significant public-health challenges. Its work combined diagnostic development with vaccine research and manufacturing capabilities. Early activities included rapid and Western blot diagnostic kits for malaria, tuberculosis, and HIV. The company reported that its screening programs were used in more than 30 countries and that, between 1999 and 2002, it screened approximately two million pregnant women in Southeast Asia for HIV. The stated public-health purpose of that program was to identify HIV-positive mothers so that hospitals could provide antiretroviral treatment and reduce the risk of transmission to newborns. JNIMC also reported developing and evaluating a rapid tuberculosis test. A study using 400 tuberculosis-positive and tuberculosis-negative serum samples from hospitals in India examined the performance of a test using multiple Mycobacterium tuberculosis antigens. According to the company’s account, combining antigens improved the test’s diagnostic specificity and sensitivity. These activities positioned JNIMC as a development-oriented supplier rather than a conventional consumer healthcare brand. The company subsequently invested in vaccine research and production infrastructure. Its manufacturing plans centered on bacterial polysaccharide and conjugate-vaccine processes, including seed-bank preparation, media preparation, fermentation, cell harvesting, centrifugation, purification, ultrafiltration, formulation, vial filling, and freeze-drying. The described facility incorporated biosafety-level-2 laboratory arrangements, clean utilities, water-for-injection systems, clean steam, process chilling, compressed air, clean-in-place systems, and supervisory control and data acquisition systems. The planned facility was described as covering approximately 32,000 square feet, with a proposed 10,000-square-foot automated unit and an intended annual capacity of up to 10 million vaccine doses. A major expansion occurred in January 2009, when JNIMC acquired vaccine-manufacturing facilities in Omaha from Biocor, a Pfizer subsidiary. The acquired site consisted of three buildings totaling approximately 71,749 square feet and was designed for production under U.S. and European regulatory manufacturing standards. JNIMC retained the Starwood containment facility for research and development and moved vaccine operations to the Maple Street facilities in February 2009. The additional capacity was intended to support production of meningococcal vaccines covering serogroups A, C, Y, and W-135, with a particular emphasis on demand in sub-Saharan Africa. Its most prominent reported clinical-development program was NmVac4-A/C/Y/W-135-DT, a diphtheria-conjugate meningococcal vaccine intended to prevent disease caused by four meningococcal serogroups. The company stated that Phase 1 and Phase 2 human clinical trials had been completed in California and Maryland under an investigational-new-drug framework approved by the U.S. Food and Drug Administration and the National Institutes of Health. JNIMC also described collaborations with global-health organizations, nongovernmental organizations, governments, local communities, and initiatives concerned with malaria, HIV/AIDS, tuberculosis, and other infectious diseases. Named relationships or affiliations in reference material include the Clinton Global Initiative, the Global Business Coalition, the President’s Malaria Initiative, and the Global Health Council. The company later encountered financial distress. JN Medical Corporation of Omaha filed for protection under Chapter 11 of the U.S. Bankruptcy Code in 2017, reportedly after insufficient shareholder funding. Publicly available reference material does not establish the company’s current operating status, ownership, or the ultimate disposition of its assets and programs.

JN-International Medical Corporation was established in 1998 in Oakland, Nebraska, by Dr. Jeeri R. Reddy with the assistance of Dr. Kelly F. Lechtenberg. The business originally operated under the name Jeeri Neotech International, Inc. Its early work concentrated on diagnostic technologies for infectious diseases, including malaria, tuberculosis, and HIV. The company developed rapid and Western blot testing products and pursued applications in lower-resource environments. Between 1999 and 2002, the organization reported screening roughly two million pregnant women in Southeast Asia for HIV. The purpose of the program was to identify infections during pregnancy so that healthcare providers could administer antiretroviral treatment and reduce mother-to-child transmission. JNIMC also reported evaluating a rapid tuberculosis test with serum samples from hospitals in India. That work examined a test using multiple Mycobacterium tuberculosis antigens and reported improved diagnostic performance when antigens were combined. The company stated that its diagnostic products had been used in more than 30 countries. In 2000, the corporation moved from Oakland to Omaha, Nebraska, as its activities expanded. It then developed a broader platform involving vaccine research, production, and global-health partnerships. The company described relationships with international health organizations, nongovernmental organizations, local governments, communities, and initiatives addressing malaria, HIV/AIDS, tuberculosis, and bacterial meningitis. Its intended beneficiaries were principally underserved populations in West Africa, Southeast Asia, and Latin America. JNIMC designed vaccine facilities around bacterial fermentation, formulation, purification, vial filling, and lyophilization. The planned infrastructure was described as compliant with current good manufacturing practice requirements used by the U.S. Food and Drug Administration and with European good manufacturing practice standards. It included biosafety-level-2 areas, water-for-injection systems, clean steam, oil-free compressed air, process chilling, clean-in-place systems, and industrial control systems. The facility was described as covering approximately 32,000 square feet, including a proposed 10,000-square-foot automated unit, with a target capacity of 10 million vaccine doses annually. In January 2009, JNIMC acquired Biocor vaccine-manufacturing facilities in Omaha. Biocor was identified as a Pfizer subsidiary. The acquired property comprised three buildings totaling approximately 71,749 square feet and had been designed for vaccine production under U.S. and European standards. JNIMC planned to retain its Starwood containment site for research and development while transferring vaccine operations to Maple Street in February 2009. The expanded facilities were intended to increase production capacity for meningococcal vaccines against serogroups A, C, Y, and W-135, with sub-Saharan African demand identified as a major objective. The company’s principal reported clinical program was NmVac4-A/C/Y/W-135-DT, a diphtheria-conjugate vaccine against four meningococcal serogroups. JNIMC stated that Phase 1 and Phase 2 human trials had been completed in California and Maryland under an FDA investigational-new-drug authorization involving the National Institutes of Health. It also described research and publications concerning human infectious diseases and neurological disorders. The company later suffered financial difficulties. JN Medical Corporation of Omaha filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Nebraska in 2017. Reference material links the filing to inadequate shareholder funding. The available sources do not provide a definitive account of post-bankruptcy operations, liquidation, reorganization, ownership, or the present status of the company.

• 2017

  Chapter 11 filing

  [1]JN-International Medical Corporationen.wikipedia.org

  JN Medical Corporation filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Nebraska.

• 2009

  Acquisition of Biocor facilities

  [1]JN-International Medical Corporationen.wikipedia.org

  JNIMC acquired Biocor vaccine-manufacturing facilities in Omaha and planned to move vaccine operations to the Maple Street site.

• 2002

  Completion of reported Southeast Asian HIV screening program

  [1]JN-International Medical Corporationen.wikipedia.org

  The company reported screening approximately two million pregnant women in Southeast Asia between 1999 and 2002.

• 2000

  Operations move to Omaha

  [1]JN-International Medical Corporationen.wikipedia.org

  The corporation relocated from Oakland to Omaha, Nebraska, as it expanded its research, diagnostic, and manufacturing activities.

• 1998

  Company founded in Nebraska

  [1]JN-International Medical Corporationen.wikipedia.org

  Dr. Jeeri R. Reddy founded the company in Oakland, Nebraska, with assistance from Dr. Kelly F. Lechtenberg. It initially operated as Jeeri Neotech International, Inc.

A development-focused biopharmaceutical company serving infectious-disease screening, vaccine research, and vaccine manufacturing needs in developing-country and underserved-market settings.

• Diagnostic test

  Rapid malaria diagnostic tests

  JNIMC developed rapid diagnostic products intended to support malaria screening in resource-constrained healthcare settings. The reference material identifies malaria testing as one of the company’s early product areas, although it does not specify a product trade name, regulatory status, or current availability.

• Diagnostic test

  Tuberculosis diagnostic tests

  The company developed rapid and Western blot tuberculosis diagnostic products and evaluated a rapid test using serum samples from hospitals in India. The reported evaluation involved 400 positive and negative samples and examined whether combining Mycobacterium tuberculosis antigens improved specificity and sensitivity.

• Diagnostic test

  HIV diagnostic tests

  JNIMC’s early portfolio included rapid and Western blot HIV diagnostic kits. The company also reported a large Southeast Asian screening program involving pregnant women, designed to enable treatment of HIV-positive mothers and reduce transmission to infants.

• Meningococcal conjugate vaccine

  NmVac4-A/C/Y/W-135-DT

  NmVac4-A/C/Y/W-135-DT was described as a diphtheria-conjugate vaccine intended to prevent meningococcal meningitis caused by serogroups A, C, Y, and W-135. JNIMC reported completion of Phase 1 and Phase 2 human clinical trials in California and Maryland under an FDA investigational-new-drug framework.

• 1999Southeast Asian maternal HIV screening program

  Southeast Asia

  JNIMC reported screening approximately two million pregnant women for HIV from 1999 through 2002. The program was intended to help hospitals identify HIV-positive pregnant women and provide antiretroviral treatment.

  Outcome. The company stated that the program contributed to HIV-free births by enabling treatment, but the available reference does not provide independently verified outcome statistics.

  Source

• 2017

  Chapter 11 bankruptcy filingOther

  Background

  The company experienced financial pressure and reportedly lacked sufficient shareholder funding after shareholder support had continued through 2015.

  Action taken

  JN Medical Corporation of Omaha filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the District of Nebraska.

  Aftermath

  The available sources do not document the final restructuring, liquidation, asset disposition, or subsequent operating status.

  Source

• 2009

  Acquisition of Biocor vaccine facilitiesM&A

  Background

  JNIMC sought additional manufacturing capacity for vaccines, including meningococcal products intended for demand in sub-Saharan Africa.

  Action taken

  The company acquired three Omaha buildings formerly associated with Biocor, a Pfizer subsidiary, and planned to transfer vaccine operations to the Maple Street site while retaining the Starwood facility for research and development.

  Aftermath

  The acquisition increased the company’s planned production, formulation, filling, packaging, and clinical-development capacity. The sources do not establish whether the intended capacity was fully achieved.

  Source

1. 1JN-International Medical Corporationen.wikipedia.org